Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Aug 16, 2024

BUY
$161.01 - $317.85 $25.1 Million - $49.6 Million
156,041 New
156,041 $49.4 Million
Q4 2023

Feb 13, 2024

BUY
$161.01 - $317.85 $16.8 Million - $33.2 Million
104,356 Added 201.91%
156,041 $49.4 Million
Q3 2023

Nov 15, 2023

SELL
$164.66 - $218.08 $8.63 Million - $11.4 Million
-52,432 Reduced 50.36%
51,685 $8.74 Million
Q2 2023

Aug 14, 2023

BUY
$176.32 - $240.22 $1.92 Million - $2.61 Million
10,884 Added 11.67%
104,117 $22.6 Million
Q1 2023

May 15, 2023

SELL
$161.33 - $204.36 $3.06 Million - $3.88 Million
-18,970 Reduced 16.91%
93,233 $16.9 Million
Q4 2022

Feb 14, 2023

SELL
$191.53 - $236.82 $6.5 Million - $8.04 Million
-33,941 Reduced 23.22%
112,203 $22 Million
Q3 2022

Nov 14, 2022

SELL
$123.79 - $277.42 $840,286 - $1.88 Million
-6,788 Reduced 4.44%
146,144 $32.9 Million
Q2 2022

Oct 27, 2022

BUY
$93.97 - $143.33 $2.05 Million - $3.13 Million
21,847 Added 16.67%
152,932 $19.3 Million
Q2 2022

Aug 15, 2022

BUY
$93.97 - $143.33 $2.05 Million - $3.13 Million
21,847 Added 16.67%
152,932 $19.3 Million
Q1 2022

Oct 27, 2022

SELL
$98.9 - $132.37 $2.16 Million - $2.89 Million
-21,847 Reduced 14.29%
131,085 $16.6 Million
Q1 2022

May 13, 2022

BUY
$98.9 - $132.37 $5.15 Million - $6.9 Million
52,114 Added 65.99%
131,085 $16.6 Million
Q4 2021

Feb 14, 2022

BUY
$110.64 - $159.4 $3.26 Million - $4.7 Million
29,480 Added 59.57%
78,971 $10.3 Million
Q3 2021

Nov 15, 2021

BUY
$101.2 - $125.87 $5.01 Million - $6.23 Million
49,491 New
49,491 $6.05 Million

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.